BioAtla (NASDAQ:BCAB – Get Free Report) issued its earnings results on Thursday. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($8.50) by $8.77, FiscalAI reports. The firm had revenue of $6.50 million during the quarter.
BioAtla Stock Up 2.1%
BCAB stock traded up $0.07 during mid-day trading on Thursday, reaching $3.45. 148,563 shares of the company traded hands, compared to its average volume of 49,317. The firm’s 50 day moving average price is $3.65 and its 200 day moving average price is $5.96. The stock has a market cap of $5.73 million, a price-to-earnings ratio of -0.08 and a beta of 0.78. BioAtla has a fifty-two week low of $3.12 and a fifty-two week high of $71.50.
Institutional Investors Weigh In On BioAtla
Several institutional investors have recently bought and sold shares of BCAB. Marshall Wace LLP bought a new position in BioAtla during the 4th quarter valued at $508,000. Vanguard Group Inc. raised its holdings in shares of BioAtla by 9.1% in the third quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock valued at $1,339,000 after purchasing an additional 162,647 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of BioAtla by 968.9% during the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock valued at $585,000 after purchasing an additional 1,531,994 shares in the last quarter. Millennium Management LLC boosted its holdings in BioAtla by 123.4% during the fourth quarter. Millennium Management LLC now owns 762,394 shares of the company’s stock worth $433,000 after purchasing an additional 421,072 shares during the last quarter. Finally, Jane Street Group LLC grew its position in BioAtla by 55.4% in the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after purchasing an additional 123,597 shares in the last quarter. Institutional investors own 77.23% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on BioAtla
About BioAtla
BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.
Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.
Read More
- Five stocks we like better than BioAtla
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.
